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Abstract: Circadian rhythm disruption can elicit the development of various diseases, including
breast cancer. While studies have used cell lines to study correlations between altered circadian
rhythms and cancer, these models have different genetic backgrounds and do not mirror the changes
that occur with disease development. Isogenic cell models can recapitulate changes across cancer
progression. Hence, in this study, a patient-derived breast cancer model, the 21T series, was used to
evaluate changes to circadian oscillations of core clock protein transcription as cells progress from
normal to malignant states. Three cell lines were used: H16N2 (normal breast epithelium), 21PT
(atypical ductal hyperplasia), and 21MT-1 (invasive metastatic carcinoma). The cancerous cells are
both HER2+. We assessed the transcriptional profiles of two core clock proteins, BMAL1 and PER2,
which represent a positive and negative component of the molecular oscillator. In the normal H16N2
cells, both genes possessed rhythmic mRNA oscillations with close to standard periods and phases.
However, in the cancerous cells, consistent changes were observed: both genes had periods that
deviated farther from normal and did not have an anti-phase relationship. In the future, mechanistic
studies should be undertaken to determine the oncogenic changes responsible for the circadian
alterations found.
Keywords: breast cancer; cancer progression; circadian rhythm; metastatic cells; rhythmicity
1. Introduction
The circadian clock is a hierarchical timing system that regulates physiological, be-
havioral, and metabolic functions across a 24 h day–night cycle and maintains temporal
tissue homeostasis in coordination with the external environment [1,2]. Peripheral clocks
are entrained by a central core clock located in the suprachiasmatic nucleus (SCN) and are
necessary for normal tissue functioning, including cell development [3,4]. At the molecular
level, the core clock consists of a well-characterized transcriptional–translational feedback
loop (TTFL), where CLOCK and BMAL1 bind to an E-box promoter to drive the expression
of other clock genes, including CRY and PER. Subsequently, CRY and PER accumulate in
the cytoplasm during the day to form complexes, which translocate back to the nucleus
to suppress the activity of CLOCK and BMAL1 [2]. Disrupted circadian rhythms have
been associated with different types of cancer, including but not limited to breast [5–8],
colon [9], and prostate cancers [10]. For breast cancer, in particular, epidemiological studies
have shown that long-term night shift workers have a higher risk of developing the dis-
ease [11–13]. Furthermore, both in vitro and in vivo studies have indicated that mutation
or dysregulation of clock genes can lead to the initiation of breast tumor growth and
metastases [5–8].
Among women in the United States, breast cancer is the most commonly diagnosed
cancer type, with the second highest cancer death rate following lung and bronchus can-
cer [14]. Female breast tissue is subject to more frequent remodeling than other types [15].
For example, during pregnancy, lactation, and involution, the mammary epithelium under-
goes multiple cycles of proliferation and cell death [16,17]. As a result, the mammary gland
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is more prone to abnormalities, which can result in cancer [18]. While it has been shown
that genetic mutations and epigenetic modifications contribute to breast cancer progression
and development [19,20], the molecular mechanisms of such processes are still unclear.
Various breast cancer cell lines (e.g., MCF-7, MDA-MB-231, SKBR3, and many oth-
ers) are frequently used for studying the disease and potential therapeutics for treating
it [21–23]. Although these cellular models are generally categorized into different breast
cancer subtypes [24], they each represent only a single stage of a progressive disease. As
a complementary approach, a series of cell lines representing disease progression can be
used. There are a few such models that have been used to study breast cancer develop-
ment, including the MCF10 human isogenic series [25–27] and the 4T1 syngeneic mouse
model [28,29]. While each represents different stages of cancer and can be related to human
disease, the MCF10 series was derived via laboratory-based genetic manipulations (includ-
ing an H-Ras mutation rarely found in breast cancer patients), and the 4T1 series originated
from a single, spontaneously arising mammary tumor in a BALB/c mouse. Neither may
truly reflect the natural evolution of human breast cancer.
Among progressive cancer models, the 21T series of cells is particularly relevant,
since each cell type was isolated from the same patient, who originally had infiltrating
and intraductal carcinoma and later developed metastases to the lung [30]. Four cell lines
comprise the model: H16N2, tumor-adjacent non-cancerous breast cells; 21PT, Atypical
Ductal Hyperplasia (ADH) cells, which are non-tumorigenic and non-metastatic; 21NT,
Ductal Carcinoma In Situ (DCIS), which are tumorigenic and non-metastatic; and 21MT,
Invasive Metastatic Carcinoma (IMC), which are both tumorigenic and metastatic. Two
distinct populations exist within the 21MT cell line, which was further separated into
21MT-1 and 21MT-2. 21MT-1 are highly heterogeneous, tend to grow in clusters, and do
not form confluent monolayers, while 21MT-2 are homogeneous polygonal cells that grow
as monolayers [30]. All cancerous cells of the 21T series overexpress ERBB2 compared to
normal H16N2 cells [30]. ERBB2 encodes the human epidermal growth factor receptor
2 (HER2), which is overexpressed, amplified, or both in several human malignancies
including breast, ovarian, and colon cancers [31]. Overexpression of HER2 in human tumor
cells is closely associated with increased angiogenesis, higher rates of cell survival, and
poor clinical outcomes [32].
Disruption of circadian rhythms has been shown to trigger cancer development, and
vice versa, malignant transformations have led to disturbances of circadian clocks [5–8,13].
In one of our previous studies, we showed that circadian clocks are disrupted across the
MCF10 series of cells representing human breast cancer [33]. We found that from benign to
metastatic states, PER2 exhibited relatively stable oscillations compared to BMAL1, whose
periods were altered over a wide circadian range. As mentioned above, while the MCF10
series represents progressive stages of breast cancer, it originated with an H-Ras mutation,
not commonly found in patients with the disease. To evaluate circadian changes in a
more relevant model, we used the human 21T series of cells in the present study. This
work represents the first assessment of circadian oscillations in a patient-derived model of
breast cancer.
We used three cell lines from the 21T series, H16N2, 21PT, and 21MT-1, representing
disease progression from benign to metastatic, to determine changes in the expression
profiles of core circadian clock genes. We focused on a positive and negative component of
the molecular clock oscillator, BMAL1 and PER2, respectively. The mRNA expressions of
BMAL1 and PER2 were tracked in a time-dependent manner via RT-PCR assessments. Our
transcriptional data indicate that the non-oncogenic H16N2 cells possess robust circadian
patterns, while 21PT and 21MT-1 have consistently less reliable rhythms, with altered
characteristics. These results support our hypothesis that circadian rhythms deviate from
normal when cells undergo malignant transformations. In further studies, a luciferase or
fluorescent reporter should be used to track the promoter activity of clock genes and/or
protein expression to generate high-resolution data for a complete assessment of circadian
parameters in this model.
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2. Results
In the current study, we sought to evaluate circadian alterations in a progressive,
patient-derived breast cancer model to ascertain whether changes occurred with disease
status. The 21T series of cell lines is considered a unique experimental model of breast
cancer progression, since there are no other models that originated from a single patient.
We used three cell lines from the human breast cancer 21T series, H16N2, 21PT, and 21MT-1,
which were isolated from a single patient and have the same genetic background but
different characteristics. H16N2 is derived from the normal epithelia, 21PT is derived
from atypical ductal hyperplasia, and 21MT-1 is derived from the pleural effusion of lung
metastasis [30]. This is an excellent model to recapitulate the de novo processes arising
during breast cancer evolution.
We focused on the expression of two core circadian clock components, one from the
positive and the other the negative arm of the feedback loop, BMAL1 and PER2, respectively.
mRNA expression of both was evaluated for each of the three 21T cell lines, using RT-PCR
(Figure 1), with sampling once every four hours from three biological replicates per cell
line, over the course of two cycles from two separate experiments. We sought to determine
whether each time series was rhythmic and, if so, its circadian properties (such as peak
time; Table 1). To assess rhythmicity, we chose multiple, complementary methods that
allowed for replicates and were flexible with respect to waveform and missing data: RAIN
(arbitrary waveform) [34], a Lomb–Scargle permutation test (allows for missing data) [35],
JTK-Cycle (compares reference curves to data) [36], and ECHO (fits data to a sine curve
with amplitude changes over time) [37]. To assess circadian properties and the quality of
rhythmicity, we fit each time series (with replicates) to a damped cosine curve.
Figure 1. Relative mRNA expression of (A) BMAL1 and (B) PER2 across the 21T series of cells. Shown are the mRNA
expression levels relative to the mean over time for each biological replicate (sample number (n) was 6 for all but 4 time
points in 21MT-1, where n = 5). The experiment was conducted twice (n = 3 for each); open and closed circles are used to
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differentiate between the two. The median and best-fit damped cosine curves are shown in blue and red, respectively. The
coefficient of determination (R2) indicates a lack of fit for BMAL1 21MT-1 (R2 = −0.01), low-quality fits for PER2 in H16N2
(R2 = 0.27) and PER2 in 21MT-1 (R2 = 0.46), and medium-quality fits for the remaining curves (R2 = 0.58 for BMAL1 in
H16N2, 0.84 for PER2 in 21PT, and 0.86 for BMAL1 in 21MT-1).
Table 1. Circadian parameters for BMAL1 and PER2 transcripts.
Cell Line Transcript
H16N2 21PT 21MT-1
BMAL1 PER2 BMAL1 PER2 BMAL1 PER2
Baseline 0.910 ± 0.066 0.485 ± 0.050 0.344 ± 0.046 0.254 ± 0.040 NA 0.876 ± 0.065
Amplitude 0.432 ± 0.066 0.309 ± 0.052 0.085 ± 0.047 0.173 ± 0.032 NA 0.208 ± 0.061
Damping Rate (1/h) −0.015 ± 0.005 −0.011 ± 0.006 −0.050 ± 0.018 −0.028 ± 0.058 NA −0.026 ± 0.009
Phase (h) 11.402 ± 0.412 26.952 ± 0.362 6.001 ± 1.337 31.473 ± 0.711 NA 27.033 ± 0.479
Slope (/h) 0.003 ± 0.002 0.018 ± 0.002 0.023 ± 0.0029 0.032 ± 0.002 NA 0.006 ± 0.003
Period (h) 26.546 ± 0.526 26.470 ± 0.728 35.745 ± 1.905 30.621 ± 1.238 NA 27.206 ± 0.910
Error shown indicates standard error. Because curve fitting failed to represent the variance in the data (resulting in a lack of fit),
characteristics associated with BMAL1 transcripts from 21MT-1 cells are not included (NA = not applicable).
All tests for rhythmicity indicated that the non-oncogenic H16N2 and non-tumorigenic,
non-metastatic 21PT cells are rhythmic, where p < 0.001 for each. The patterns for the
BMAL1 and PER2 transcripts from 21MT-1 cells were found to be rhythmic using most tests
(p < 0.001), with the exception of the Lomb–Scargle permutation test for BMAL1, where
p = 0.08. Given that each data set was determined to be rhythmic by more than one test,
we sought to further assess the characteristics of the oscillation patterns.
The normal breast epithelial H16N2 cells showed BMAL1 peaks at ~12–16 h and
32–36 h, while those for PER2 were at ~0–4 h and ~24–28 h. Hence, as expected for these
positive and negative elements of the core clock, the phase difference between the two
is approximately 12 h, with oscillation patterns in opposition to each other. A slowly
amplifying cosine curve with an increasing baseline fit the data relatively well, with the
exception of the first time point for PER2 (R2 = 0.58 for BMAL1 and 0.27 for PER2). Over
48 h, the baseline of relative expression increased by 0.16 for BMAL1 and 0.86 for PER2,
and the oscillations grew exponentially with rates of 0.02/h for BMAL1 and 0.01/h for
PER2 (Table 1, Tables S1 and S2). It also estimated peak times, where BMAL1 peaked
11.4 h and PER2 peaked 0.5 h into each cycle. The periods of both BMAL1 and PER2 were
determined to be 26.5 h with a small estimation error (BMAL1 95% CI: 25–27.7 h; PER2
95% CI: 25–28.2 h).
The 21PT (non-tumorigenic and non-metastatic) cells showed oscillations with in-
creasing amplitude. Visual inspection shows different phases from H16N2 with BMAL1
peaking at ~16–20 h and 40–44 h, while PER2 peaks at ~8–12 h and 28–32 h. We confirmed
the rhythmic patterns were different with robustDODR applied to the time series after
removing a linear trend (p < 0.001) [38], comparing each reporter across cell lines. Unlike
in the normal cells, the transcriptional patterns here were not anti-phase but still had
consistent changes (an approximately 8 h offset) for both BMAL1 and PER2 in all samples.
Curve fitting also yielded reasonable fits for this cell line (R2 = 0.86 for BMAL1 and 0.84 for
PER2; Table 1, Tables S3 and S4). Compared to H16N2 cells, 21PT oscillations showed
larger growth rates (0.05/h for BMAL1 and 0.03/h for PER2) and steeper baselines (relative
expression of BMAL1 increased by 1.09 over 48 h and PER2 by 1.54). The periods were
also both longer than those of H16N2 transcripts, and there was more uncertainty in their
estimates. The 95% confidence interval for the period of BMAL1 was 32–42 h for PER2 was
28.4–34.3 h.
The 21MT-1 (tumorigenic, metastatic) cells showed oscillations with the least circadian
characteristics. Compared to H16N2, the transcriptional patterns for both BMAL1 and PER2
were statistically different (robustDODR applied to linearly de-trended time series was
p < 0.001). For BMAL1, curve fitting failed to explain the variance in the data (R2 = −0.01),
so we do not report circadian parameters. For PER2, the time series for 21MT-1 shows less
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reliable estimates of parameters and is less sinusoidal (R2 = 0.46). Confidence intervals for
the parameter estimates of PER2 are wide (95% CI for period: 25–29.4 h; 95% CI for growth
rate: 0.008–0.04; Table S5). As in the 21PT cells, there were only 8 h between the peaks of
BMAL1 (8 h into each cycle) and PER2 (0 h into each cycle).
Additionally, to assess possible outcomes of mRNA expression changes at the protein
level, we conducted time-course Western blot analyses for BMAL1 and PER2 with the
three members of the 21T series of cells evaluated above (Figure S1). We fit each of the
time series to damped cosine curves (Figure S2). Unlike for mRNA expression patterns,
the sinusoidal curves could not be adequately fit to the time series, resulting in low
goodness-of-fit measures. BMAL1 and PER2 were not observed to have a consistent phase
relationship. While some of the statistical tests for rhythmicity identified particular time
series as rhythmic (Tables S6 and S7), these results were too inconsistent to be considered
reliable, as confirmed by visual inspection. This outcome is perhaps due to the nature of
the technique, discussed further below.
3. Discussion
Various experimental platforms have been used to investigate the correlation between
altered circadian rhythms and cancer development. These include murine models with
spontaneously developing or implanted tumors [39,40], individual cancer cell lines rep-
resenting specific subtypes (e.g., MDA-MB-231 or MCF7, as mentioned above) [8,41,42],
and series of cells representing cancer progression (e.g., 4T1 or MCF10 series, as mentioned
above) [33,43]. Studies using these models typically show that the expression of clock
genes and/or proteins is disrupted (i.e., with arrhythmic oscillation patterns or diminished
expression levels) via RT-PCR or Western blotting assessments. However, the data obtained
do not reflect progressive oncogenic changes, since non-related cell lines have diverse
genetic backgrounds, and the other models were not derived from patients carrying breast
cancer. At the same time, assessments in clinical studies often involve only a single time
point [6,7,44,45]. However, the nature of circadian rhythms is dynamic, and it is important
to carry out direct comparisons as a function of time. We recognize the difficulty in obtain-
ing/using patient samples in such a manner, and so, in the present study, we used primary
and metastatic tumor cells along with those of the normal breast epithelium, derived from
the same individual, to directly compare circadian properties in a time-dependent manner.
The foundation of circadian rhythmicity is the oscillation of molecular clocks for a
period of approximately 24 h [46,47]. During 24 h cycling, the peak times of positive and
negative core clock regulators (i.e., BMAL1 and PER2, respectively) exhibit a nearly 12 h
delay from one another, resulting in an anti-phase relationship [46]. While this is the case in
healthy cells, in disease states, various alterations (e.g., changes to period [47], phase [48],
and amplitude [49]) may occur. As shown in Figure 1 and Table 1, BMAL1 and PER2
transcripts from normal breast epithelial H16N2 cells showed rhythmic, anti-phase mRNA
oscillations (~12 h differences in peak times) with similar periods that were close to 24 h
(estimates were 26.5 h for both) and good fits. However, longer and dissimilar periods
(32.0 h for BMAL1 and 30.5 h for PER2 in 21PT; 30.5 h for BMAL1 and 27.1 h for PER2 in
21MT-1), and altered phase relationships (~8 h shifts in peak times between BMAL1 and
PER2) were found in the cancerous 21PT (ADH) and 21MT-1 (IMC) cells.
Few studies have analyzed changes in circadian characteristics using progressive
cancer models, and this is the first such study in a disease-relevant model of breast cancer.
Nonetheless, we compared our findings to those of others and strikingly observed simi-
larities. For example, Relógio et al., discovered that metastatic human skin and colorectal
cancer cell lines tended to have longer periods and altered phases compared to the respec-
tive normal epithelial cells [47,50]. Deviations from period and phase are also seen in our
data, where 21PT cells exhibited consistent changes (i.e., ~8 h phase offset with similar
growth rates) for BMAL1 and PER2, while 21MT-1 showed contrasting alterations for the
two genes (i.e., ~8 h phase offset with two opposing growth trends, one increasing and
the other decreasing) and the worst sinusoidal curve fits overall. It is surprising to us that
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different cancers can have similar changes in circadian characteristics. Broadly, our results
support the hypothesis that circadian rhythms are increasingly disrupted in breast cancer.
Although it is unclear how circadian changes occur in the cancerous 21PT and 21MT-1
cells, molecular profiling of the cells may provide some clues. Several studies have charac-
terized the genetic profiles of cells from the 21T series [30,51–54]. Band et al., showed that
compared to normal epithelial H16N2 cells, the others were HER2 positive (overexpressing
ERBB2) [30]. It is known that ERBB2 is closely associated with NR1D1 [55], the gene that
encodes REV-ERBα (a clock protein involved in the secondary clock TTFL), and high levels
of NR1D1 have frequently been found in breast cancer patients [56]. In addition to being
HER2 positive, 21MT-1 cells had hyper-activated p-Ser473 Akt [52], a kinase involved in
the PI3K/Akt/mTOR pathway frequently activated in breast cancer [57,58]. AKT phos-
phorylates CLOCK and BMAL1 and inhibits their nuclear localization [59,60], and the
mTOR pathway has been shown to regulate circadian entrainment in the SCN [61]. Taken
together, abnormal ERBB2/NR1D1 expression and activated Akt/mTOR pathways may
all contribute to the prolonged periods and altered phases of BMAL1 and PER2 in the
cancerous 21PT and 21MT-1 cells. Both aspects should be examined further to determine
their potential contributions to altered circadian oscillations.
To evaluate whether changes in transcriptional expression can be detected at the
translational level, we performed time-course Western blot analyses of BMAL1 and PER2
in the three cell lines from the 21T series. Our results showed that there was no clear and
consistent phase relationship between BMAL1 and PER2 in any of them (Figures S1 and S2).
Although some statistical analyses revealed rhythmicity in certain expression patterns
(Tables S6 and S7), it is likely that the changes were too small to be reliable. Several studies
have investigated temporal changes in clock protein expression using different disease
models; however, while some showed clear and detectable protein oscillations [62,63],
others did not, perhaps due to the low resolution of Western blotting [64,65]. We also
noted subtle changes in GAPDH expression over time; however, the minor instability of a
reference protein has been shown previously in various cell models [50,66,67].
The poor correlation between observed mRNA and protein expression could also
be induced by changes to transcriptional regulation, post-transcriptional modifications,
protein half-lives, and technical errors and noise in either or both mRNA and protein
experiments [68–70]. As an example, Robles et al., showed that post-transcriptional mod-
ifications caused a phase delay of 6 h between cycling transcripts and corresponding
proteins [69]. Future studies with this system should use luciferase reporters to acquire
high-resolution data at both the promoter and translational levels, which will enable more
detailed visualizations of oscillations and thorough analyses.
4. Materials and Methods
4.1. Cell Culture
H16N2, 21PT, and 21MT-1 cell lines were obtained from Prof. D. Joseph Jerry (Veteri-
nary and Animal Sciences, UMass Amherst, MA, USA), who received them directly from
Dr. Vimla Band, who originally isolated the cells. Cells were maintained in MEM (Gibco,
Waltham, MA, USA), with 1% penicillin–streptomycin (Gibco), 1 mM HEPES (Hyclone,
Logan, UT, USA), 1 mM sodium pyruvate (Gibco), 2 mM L-glutamine (Gibco), 10% fetal
bovine serum (FBS; Corning, Corning, NY, USA), 15 µg/mL gentamicin (Fisher Scientific,
Waltham, MA, USA), 1 µg/mL insulin (Sigma, St. Louis, MO, USA), 12.5 ng/mL epidermal
growth factor (EGF; Gibco), and 1 µg/mL hydrocortisone (Sigma). All cells were incubated
at 37 ◦C under 5% CO2.
4.2. Synchronization of Cells by Serum Shock
A 2 mL volume of cells at a density of 2 × 105 cells/mL was plated in 35 mm culture
dishes and incubated for approximately 24 h to reach 100% confluence. Culture media
were discarded, and cells were washed once with 2 mL of phosphate-buffered saline (PBS;
Gibco). Cells were then starved in MEM medium without any supplements for 12 h. After
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starvation, cells were serum shocked using growth medium containing 50% FBS for 2 h,
followed by a wash with PBS, and returned to starvation conditions (culture in MEM
medium without any supplements).
4.3. RNA Extraction and cDNA Synthesis
Cells were collected at the first time point immediately following serum shock (T = 0)
and every 4 h thereafter for 48 h. Total RNA was extracted via TRIzol Reagent (Gibco)
according to the manufacturer’s instructions. Briefly, 1 mL of TRIzol was added to lyse
the cells, and cell lysates were transferred to microcentrifuge tubes. Cell lysates were
incubated at rt for 5 min to allow complete dissociation of nucleoprotein complexes. After
the addition of 200 µL chloroform per 1 mL of TRIzol, samples were shaken vigorously by
hand for 15 s and incubated at rt for 3 min. Samples were then centrifuged at 12,000× g
for 15 min at 4 ◦C to separate the RNA-containing, upper aqueous phase, from the lower
chloroform phase. RNA samples were further purified via the PureLink RNA kit (Ambion,
Austin, TX, USA) according to the manufacturer’s instructions. Total RNA concentration
was determined by Nanodrop UV/Vis (Thermo Fisher Scientific, Waltham, MA, USA). A
1 µg amount of total RNA was reverse-transcribed to cDNA using 50 µM random hexamers,
40 U/µL RNaseOut, 10 mM dNTPs, and 200 U/µL SuperScript IV Reverse Transcriptase
(Thermo Fisher Scientific).
4.4. Real-Time PCR (RT-PCR)
RT-PCR was performed in 96-well plates. Each reaction (20 µL per well) consisted of
100 ng cDNA, 10 µL iTaq universal SYBR Green Supermix (Bio-Rad, Hercules, CA, USA),
4 µM of each respective forward and reverse primer, and RNAse free water (Fisher) to a final
volume of 20 µL. All DNA primers were purchased from Integrated DNA Technologies
(Coralville, IA, USA). The following sequences were used: GAPDH forward (5′-CTT CTT
TTG CGT CGC CAG CC-3′), reverse (5′-ATT CCG TTG ACT CCG ACC TTC-3′); BMAL1
forward (5′-CTA CGC TAG AGG GCT TCC TG-3′), reverse (5′-CTT TTC AGG CGG TCA
GCT TC-3′); PER2 forward (5′-TGT CCC AGG TGG AGA GTG GT-3′), reverse (5′-TGT CAC
CGC AGT TCA AAC GAG-3′). After brief centrifugation, samples were analyzed via the
CFX Connect real-time system (Bio-Rad) programmed with an initial activation at 95 ◦C for
3 min, followed by 40 cycles of 95 ◦C denaturation for 10 s, and 60 ◦C annealing/extension
for 30 s. Relative BMAL1 and PER2 expression levels were determined by comparing the
Ct values of BMAL1 and PER2 to GAPDH controls via the 2∧∆∆Ct method [71]. Three
biological replicates and three technical replicates per biological replicate were analyzed
for each condition.
4.5. Rhythmicity Tests
Rhythmicity tests were performed using R packages (www.r-project.org). RAIN (rain
v1.14.0) was used for a period of 24 h. The Lomb–Scargle permutation test (randlsp from
lomb package v1.2; using the peak of the periodogram in the range of 6 to 50 h) used 5000
random permutations [35]. Metacycle v1.2.0 [72] was used to run the JTK-Cycle test. ECHO
(echo.find v3.0) was used to test for periodicity in the range of 24 to 32 h, after linearly
de-trending [37]. Following the tests for rhythmicity, a test for differential rhythmicity was
used for each pair of cell lines with the DODR R package (v.0.99.2) [38].
4.6. Curve Fitting
Each mRNA time series (with 5–6 biological replicates) was fit to a “damped” cosine




+ mt + b, where A is amplitude, λ is
damping rate, θ is phase, τ is intrinsic period, m is baseline slope, and b is y-intercept. λ
was allowed to vary between −0.05 (a growing curve) and 0.05 (a damping curve). As
in ECHO, each point was weighted by the inverse of the variance at its time step. The R
function nls was used to estimate the coefficients and compute the 95% confidence intervals.
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5. Conclusions
In this study, we report the first findings of circadian disruption in a progressive series
of human, breast cancer patient-derived cells. We evaluated the oscillations of mRNA
expression for two core clock components, BMAL1 and PER2, in a time-dependent manner,
in cell lines across the 21T series. Normal epithelial H16N2 cells displayed standard
oscillation patterns. The two cancerous cell types, 21PT and 21MT-1, exhibited periods
that deviated farther from 24 h and were less consistent between the BMAL1 and PER2
transcripts, which were also not anti-phase with the expected 12 h differences in peak times.
Our analyses of protein expression revealed that neither BMAL1 nor PER2 had clear,
anti-phase relationships in any of the cells. This is likely due to the low-resolution feature
of Western blotting, where changes were too subtle to be detected. Taken together, our data
support the hypothesis that circadian rhythms are increasingly disrupted with malignancy
in breast cancer. To provide a better understanding and more accurate analyses of these
altered oscillations, luciferase reporters and real-time luminometry should be used in the
future. Furthermore, next-generation sequencing can be utilized to assess connections
between cancer and circadian pathways, and may provide insights to how they affect one
another. Understanding the contributions of circadian rhythms and their effects on breast
cancer development will be pivotal to understanding the roles of the clock in this and
other diseases.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/clockssleep3040042/s1, Table S1: Estimates and confidence intervals for BMAL1 mRNA
time series from H16N2. Table S2: Estimates and confidence intervals for PER2 mRNA time series
from H16N2. Table S3: Estimates and confidence intervals for BMAL1 mRNA time series from
21PT. Table S4: Estimates and confidence intervals for PER2 mRNA time series from 21PT. Table S5:
Estimates and confidence intervals for PER2 mRNA time series from 21MT-1. Table S6: p-values from
rhythmicity tests for the BMAL1 protein time series. Table S7: p-values from rhythmicity tests for the
PER2 protein time series. Figure S1: All Western blots for BMAL1 and PER2 for H16N2 cells, 21PT
cells, and 21MT-1 cells. Figure S2: Relative protein expression of BMAL1 and PER2 in the 21T series
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